AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 2477204 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 216
Study 799974 — intervention group
Group type: EXPERIMENTAL
Intervention: Metoprolol (150 and 300 mg/day)
Number of subjects: 10
Study 799974 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (120 and 240 mg/day)
Number of subjects: 10
Study 799974 — intervention group
Group type: COMPARATOR
Intervention: Placebo (3 and 6 tablets per day)
Number of subjects: 10
Study 12596619 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (3 micrograms/kg)
Number of subjects: 60
Study 12596619 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 60
Study 31335434 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver-impregnated NPWT
Number of subjects: 66
Study 31335434 — intervention group
Group type: COMPARATOR
Intervention: Conventional NPWT
Number of subjects: 66
Study 28887592 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressant DTCA with portrayals of discrimination, cognitive separation, and stereotyping (DCSS)
Number of subjects: 0
Study 28887592 — intervention group
Group type: COMPARATOR
Intervention: No-exposure control
Number of subjects: 0
Study 27179825 — intervention group
Group type: EXPERIMENTAL
Intervention: EECP treatment (35 1‐h sessions)
Number of subjects: 30
Study 25409886 — intervention group
Group type: EXPERIMENTAL
Intervention: Stepped care
Number of subjects: 60
Study 25409886 — intervention group
Group type: COMPARATOR
Intervention: Intensive psychological therapy alone
Number of subjects: 60
Study 21745039 — intervention group
Group type: EXPERIMENTAL
Intervention: Gain-framed messages
Number of subjects: 1108
Study 21745039 — intervention group
Group type: EXPERIMENTAL
Intervention: Loss-framed messages
Number of subjects: 1108
Study 21745039 — intervention group
Group type: COMPARATOR
Intervention: No-message control condition
Number of subjects: 1108
Study 20711429 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 200775 at 0.03 mg/kg/h
Number of subjects: 18
Study 20711429 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 200775 at 0.75 mg/kg/h
Number of subjects: 18
Study 20711429 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% sodium chloride solution)
Number of subjects: 18
Study 20711429 — intervention group
Group type: EXPERIMENTAL
Intervention: ZK 200775 (both doses)
Number of subjects: 18
Study 19084894 — intervention group
Group type: EXPERIMENTAL
Intervention: B-PREPARED scale
Number of subjects: 460
Study 16154019 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug-eluting stents (DES)
Number of subjects: 826
Study 16154019 — intervention group
Group type: COMPARATOR
Intervention: Bare-metal stents (BMS)
Number of subjects: 826
Study 12383382 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 300
Study 9575984 — intervention group
Group type: EXPERIMENTAL
Intervention: Prior time awake (PRW) of 4, 8, and 12 hours before sleep
Number of subjects: 8
Study 9575984 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of day (TOD) with respect to the circadian rhythm
Number of subjects: 8
Study 9575984 — intervention group
Group type: EXPERIMENTAL
Intervention: Time of day (TOD) and prior time awake (PRW)
Number of subjects: 8
Study 7874634 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 2496240 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavior therapy program for urinary incontinence (13 weeks)
Number of subjects: 133
Study 2496240 — intervention group
Group type: COMPARATOR
Intervention: Usual incontinence-related care (Control)
Number of subjects: 133
Study 610325 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination induction therapy with vincristine and prednisolone
Number of subjects: 134
Study 610325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic therapy (721-A) with intermittent high-dose infusion of methotrexate
Number of subjects: 134
Study 610325 — intervention group
Group type: EXPERIMENTAL
Intervention: Three courses of 'prophylactic' intrathecal methotrexate (Mtx) and hydrocortisone (HDC)
Number of subjects: 134
Study 610325 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic intrathecal medication during remission or combination therapy with 2,400 rads cranial irradiation plus intrathecal medication
Number of subjects: 134
Study 610325 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients maintained without further chemotherapy after complete remission
Number of subjects: 134
Study 610325 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients taken off therapy
Number of subjects: 134
Study 610325 — intervention group
Group type: EXPERIMENTAL
Intervention: Observation period
Number of subjects: 134
Study 31781755 — intervention group
Group type: EXPERIMENTAL
Intervention: Filgotinib, a selective JAK1 inhibitor
Number of subjects: 0
Study 31781755 — intervention group
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Number of subjects: 0
Study 31781755 — intervention group
Group type: COMPARATOR
Intervention: Tofacitinib, a pan‐JAK inhibitor
Number of subjects: 0
Study 31307505 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.75 mg midazolam
Number of subjects: 614
Study 31307505 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 614
Study 28558843 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted de-implementation strategy (interactive education, feedback on blood management performance, comparison with benchmark hospitals)
Number of subjects: 924
Study 28558843 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted de-implementation strategy
Number of subjects: 924
Study 28558843 — intervention group
Group type: COMPARATOR
Intervention: Control hospitals
Number of subjects: 924
Study 25952317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib 400mg twice daily followed by sunitinib 50mg once daily (4 wk on, 2 wk off)
Number of subjects: 365
Study 25952317 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib 50mg once daily (4 wk on, 2 wk off) followed by sorafenib 400mg twice daily
Number of subjects: 365
Study 25952317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib followed by sunitinib (So‐Su)
Number of subjects: 365
Study 25952317 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib followed by sorafenib (Su‐So)
Number of subjects: 365
Study 25952317 — intervention group
Group type: EXPERIMENTAL
Intervention: So‐Su
Number of subjects: 365
Study 25952317 — intervention group
Group type: COMPARATOR
Intervention: Su‐So
Number of subjects: 365
Study 25952317 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib
Number of subjects: 365
Study 25952317 — intervention group
Group type: COMPARATOR
Intervention: Sunitinib
Number of subjects: 365
Study 24237806 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone maximal restraint with no weight force (PMR-0)
Number of subjects: 25
Study 24237806 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone maximal restraint with 50 lbs added (PMR-50)
Number of subjects: 25
Study 24237806 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone maximal restraint with 100 lbs added (PMR-100)
Number of subjects: 25
Study 24237806 — intervention group
Group type: COMPARATOR
Intervention: Supine (SU)
Number of subjects: 25
Study 24237806 — intervention group
Group type: EXPERIMENTAL
Intervention: Prone (PR)
Number of subjects: 25
Study 22092152 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment (pelvic floor muscle exercises, urge suppression techniques, delayed voiding)
Number of subjects: 143
Study 22092152 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy (individually titrated, extended‐release oxybutynin, 5‐30 mg/d)
Number of subjects: 143
Study 22092152 — intervention group
Group type: EXPERIMENTAL
Intervention: Behavioral treatment
Number of subjects: 143
Study 22092152 — intervention group
Group type: EXPERIMENTAL
Intervention: Drug therapy
Number of subjects: 143
Study 22092152 — intervention group
Group type: COMPARATOR
Intervention: Both interventions
Number of subjects: 143
Study 19673667 — intervention group
Group type: EXPERIMENTAL
Intervention: torasemide-PR (10-40 mg daily)
Number of subjects: 142
Study 19673667 — intervention group
Group type: COMPARATOR
Intervention: furosemide (40-160 mg daily)
Number of subjects: 142
Study 19673667 — intervention group
Group type: EXPERIMENTAL
Intervention: torasemide-PR
Number of subjects: 142
Study 16957977 — intervention group
Group type: EXPERIMENTAL
Intervention: Bioglue application in the mucosa anastomosis area
Number of subjects: 200
Study 16957977 — intervention group
Group type: COMPARATOR
Intervention: Control group (no Bioglue application)
Number of subjects: 200
Study 16957977 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (Bioglue and Control)
Number of subjects: 200
Study 14724812 — intervention group
Group type: EXPERIMENTAL
Intervention: Unsated ultrathin EGD (UT‐EGD)
Number of subjects: 80
Study 14724812 — intervention group
Group type: COMPARATOR
Intervention: Sedated conventional EGD (C‐EGD)
Number of subjects: 80
Study 10966703 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment
Number of subjects: 302
Study 10966703 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment
Number of subjects: 302
Study 10966703 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment (in patients aged 2 years or younger with grade IV VUR, bilateral VUR, or renal scars)
Number of subjects: 302
Study 10966703 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgical treatment (in patients with unilateral renal scarring or thin parenchyma)
Number of subjects: 302
Study 10966703 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical treatment (in patients with bilateral renal scarring)
Number of subjects: 302
Study 8990731 — intervention group
Group type: EXPERIMENTAL
Intervention: Massage therapy (three 15-minute massages daily for 10 days)
Number of subjects: 28
Study 8990731 — intervention group
Group type: COMPARATOR
Intervention: Control group (no massage therapy)
Number of subjects: 28
Study 1731418 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine 120 mg daily
Number of subjects: 1064
Study 1731418 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1064
Study 6539062 — intervention group
Group type: EXPERIMENTAL
Intervention: All-plant protein diet (soybean protein and soy milk)
Number of subjects: 5
Study 6539062 — intervention group
Group type: COMPARATOR
Intervention: Control diet (mixed protein from meat, dairy products, and plant sources)
Number of subjects: 5
Study 31363811 — intervention group
Group type: EXPERIMENTAL
Intervention: Subfascial implant placement
Number of subjects: 20
Study 31363811 — intervention group
Group type: COMPARATOR
Intervention: Subglandular implant placement
Number of subjects: 20
Study 29465751 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy plus surgery (CS) group
Number of subjects: 497
Study 29465751 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-responders (TRG4–5)
Number of subjects: 497
Study 29465751 — intervention group
Group type: EXPERIMENTAL
Intervention: Lymph node (LN) status post-NAC
Number of subjects: 497
Study 27255463 — intervention group
Group type: EXPERIMENTAL
Intervention: Partnered pharmacist charting
Number of subjects: 473
Study 27255463 — intervention group
Group type: COMPARATOR
Intervention: Standard medical staff charting
Number of subjects: 473
Study 25231089 — intervention group
Group type: EXPERIMENTAL
Intervention: Group A: lansoprazole 30 mg bid, amoxicillin 1.0 g tid, rifabutin 150 mg bid for 7 days
Number of subjects: 59
Study 25231089 — intervention group
Group type: COMPARATOR
Intervention: Group B: lansoprazole 60 mg bid, amoxicillin 1.0 g tid, rifabutin 150 mg bid for 7 days
Number of subjects: 59
Study 22313068 — intervention group
Group type: EXPERIMENTAL
Intervention: L-arginine
Number of subjects: 53
Study 22313068 — intervention group
Group type: COMPARATOR
Intervention: Control (blood cardioplegia without L-arginine)
Number of subjects: 53
Study 19837545 — intervention group
Group type: COMPARATOR
Intervention: Moderate lipid-lowering therapy with low-dose atorvastatin (10 mg-20 mg)
Number of subjects: 140
Study 19837545 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive lipid-lowering therapy with high-dose atorvastatin (80 mg)
Number of subjects: 140
Study 16533867 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaraná extract 37.5 mg
Number of subjects: 26
Study 16533867 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaraná extract 75 mg
Number of subjects: 26
Study 16533867 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaraná extract 150 mg
Number of subjects: 26
Study 16533867 — intervention group
Group type: EXPERIMENTAL
Intervention: Guaraná extract 300 mg
Number of subjects: 26
Study 16533867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 16239201 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine at a dose equal to the mean of their total daily CSII basal insulin dose (group 1:1)
Number of subjects: 38
Study 16239201 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin glargine at a dose of 1.2 times the mean of their total daily CSII basal insulin dose (group 1:1.2)
Number of subjects: 38
Study 16239201 — intervention group
Group type: COMPARATOR
Intervention: Both groups (1:1 and 1:1.2)
Number of subjects: 38
Study 12204788 — intervention group
Group type: COMPARATOR
Intervention: 4% Dextrin sulphate (DS) gel applied topically to the penis once per day for 14 consecutive days, left on for a minimum of 6 hours.
Number of subjects: 28
Study 12204788 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo gel applied topically to the penis once per day for 14 consecutive days, left on for a minimum of 6 hours.
Number of subjects: 28
Study 10567865 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.1% indomethacin solution
Number of subjects: 347
Study 10567865 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 347
Study 8733689 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL-2 post-ABMT (group A)
Number of subjects: 10
Study 8733689 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL-2 before BM harvesting (group B)
Number of subjects: 10
Study 8733689 — intervention group
Group type: EXPERIMENTAL
Intervention: rIL-2 regimen pre- and/or post-ABMT
Number of subjects: 10
Study 1924667 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (neuroleptic threshold doses)
Number of subjects: 0
Study 6356924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin (3 doses of 2 gm intramuscularly over 12 hours)
Number of subjects: 0
Study 6356924 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6356924 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefoxitin
Number of subjects: 0
Study 28637193 — intervention group
Group type: EXPERIMENTAL
Intervention: IPANR intervention
Number of subjects: 320
Study 28637193 — intervention group
Group type: COMPARATOR
Intervention: 5Rs (control)
Number of subjects: 320
Study 28339581 — intervention group
Group type: EXPERIMENTAL
Intervention: CRT-D
Number of subjects: 360
Study 28339581 — intervention group
Group type: COMPARATOR
Intervention: ICD
Number of subjects: 360
Study 26188849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol locks (1.5 or 3 ml 70%)
Number of subjects: 307
Study 26188849 — intervention group
Group type: COMPARATOR
Intervention: Heparin locks (1.5 or 3 ml 100 IU/ml)
Number of subjects: 307
Study 26188849 — intervention group
Group type: EXPERIMENTAL
Intervention: Ethanol locks
Number of subjects: 307
Study 24095901 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBT) for Panic Disorder, 11 sessions
Number of subjects: 361
Study 20838119 — intervention group
Group type: EXPERIMENTAL
Intervention: Airway Pressure Release Ventilation (APRV)
Number of subjects: 63
Study 20838119 — intervention group
Group type: COMPARATOR
Intervention: Low Tidal Volume Ventilation (LOVT)
Number of subjects: 63
Study 18231996 — intervention group
Group type: EXPERIMENTAL
Intervention: DK crush stenting
Number of subjects: 37
Study 18231996 — intervention group
Group type: COMPARATOR
Intervention: Classic crush stenting
Number of subjects: 37
Study 16680475 — intervention group
Group type: EXPERIMENTAL
Intervention: Saline-adrenaline-lidocaine solution injected (40 ml)
Number of subjects: 164
Study 16680475 — intervention group
Group type: COMPARATOR
Intervention: Laparoscopic cholecystectomy without hydrodissection
Number of subjects: 164
Study 15513568 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose vitamin A
Number of subjects: 2177
Study 15513568 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 2177
Study 11063905 — intervention group
Group type: EXPERIMENTAL
Intervention: Kliogest (norethisterone acetate 1 mg and oestradiol valerate 2 mg)
Number of subjects: 22
Study 11063905 — intervention group
Group type: EXPERIMENTAL
Intervention: Livial (tibolone)
Number of subjects: 22
Study 9357936 — intervention group
Group type: EXPERIMENTAL
Intervention: CMSE
Number of subjects: 0
Study 9357936 — intervention group
Group type: EXPERIMENTAL
Intervention: CMA
Number of subjects: 0
Study 9357936 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 0
Study 26559037 — intervention group
Group type: EXPERIMENTAL
Intervention: Planned individualized care and regular systematic clinical supervision (Experimental Ward)
Number of subjects: 39
Study 26559037 — intervention group
Group type: COMPARATOR
Intervention: Control Ward (no intervention)
Number of subjects: 39
Study 2873011 — intervention group
Group type: EXPERIMENTAL
Intervention: Midazolam 15 mg
Number of subjects: 60
Study 2873011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lorazepam 2.5 mg
Number of subjects: 60
Study 2873011 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 2856601 — intervention group
Group type: EXPERIMENTAL
Intervention: Ceftazidime (2 gm every eight or 12 hours)
Number of subjects: 40
Study 2856601 — intervention group
Group type: COMPARATOR
Intervention: Amikacin (500 mg every 12 hours) and Ticarcillin (3 gm every six or eight hours)
Number of subjects: 40
Study 29692206 — intervention group
Group type: EXPERIMENTAL
Intervention: Carvedilol (50 mg/day)
Number of subjects: 34
Study 29692206 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0 mg/day)
Number of subjects: 34
Study 26909489 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-05280586
Number of subjects: 220
Study 26909489 — intervention group
Group type: COMPARATOR
Intervention: rituximab-EU
Number of subjects: 220
Study 26909489 — intervention group
Group type: COMPARATOR
Intervention: rituximab-US
Number of subjects: 220
Study 25754510 — intervention group
Group type: EXPERIMENTAL
Intervention: Proaftol spray, applied as two sprayings on the site of the aphthae 3-4 times a day.
Number of subjects: 0
Study 25754510 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray, applied as two sprayings on the site of the aphthae 3-4 times a day.
Number of subjects: 0
Study 25754510 — intervention group
Group type: EXPERIMENTAL
Intervention: Proaftol spray
Number of subjects: 0
Study 25754510 — intervention group
Group type: COMPARATOR
Intervention: Placebo spray
Number of subjects: 0
Study 22989715 — intervention group
Group type: EXPERIMENTAL
Intervention: Distalizing force applied to one maxillary canine (test side)
Number of subjects: 16
Study 22989715 — intervention group
Group type: COMPARATOR
Intervention: No force applied to the contralateral canine (control side)
Number of subjects: 16
Study 22989715 — intervention group
Group type: EXPERIMENTAL
Intervention: Tension site (test)
Number of subjects: 16
Study 22989715 — intervention group
Group type: COMPARATOR
Intervention: Pressure site (control)
Number of subjects: 16
Study 19572158 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine
Number of subjects: 570
Study 19572158 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 570
Study 18942377 — intervention group
Group type: COMPARATOR
Intervention: Succinate-based food composition (SBC)
Number of subjects: 0
Study 16617618 — intervention group
Group type: EXPERIMENTAL
Intervention: New sleep staging system using five electrodes and Independent Component Analysis
Number of subjects: 14
Study 16617618 — intervention group
Group type: COMPARATOR
Intervention: Standard sleep analysis system (polysomnographic recordings)
Number of subjects: 14
Study 15328395 — intervention group
Group type: EXPERIMENTAL
Intervention: Pharmacists' proactive discharge planning program
Number of subjects: 172
Study 15328395 — intervention group
Group type: COMPARATOR
Intervention: Control group (no pharmacists' intervention)
Number of subjects: 172
Study 10945311 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg administered simultaneously with ketoconazole 200 mg
Number of subjects: 8
Study 10945311 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide 3 mg administered 12 hours before ketoconazole 200 mg
Number of subjects: 8
Study 10945311 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 200 mg administered once daily in the morning
Number of subjects: 8
Study 9493660 — intervention group
Group type: COMPARATOR
Intervention: Control: ambient temperature (tamb) = 25 degrees C, rectal temperature change (delta tre) = 0 degrees C
Number of subjects: 6
Study 9493660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-immersion: tamb = 4 degrees C, delta tre = 0 degrees C
Number of subjects: 6
Study 9493660 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-immersion: tamb = 25 degrees C, delta tre = -0.7 degrees C
Number of subjects: 6
Study 8399251 — intervention group
Group type: EXPERIMENTAL
Intervention: Appointment made by a health professional
Number of subjects: 162
Study 8399251 — intervention group
Group type: COMPARATOR
Intervention: Patient made his or her own appointment
Number of subjects: 162
Study 8399251 — intervention group
Group type: EXPERIMENTAL
Intervention: Received appointment reminder card
Number of subjects: 162
Study 8399251 — intervention group
Group type: COMPARATOR
Intervention: Did not receive appointment reminder card
Number of subjects: 162
Study 8399251 — intervention group
Group type: EXPERIMENTAL
Intervention: Older patients
Number of subjects: 162
Study 8399251 — intervention group
Group type: EXPERIMENTAL
Intervention: Previous dental visits and procedures, oral hygiene instruction, and x‐rays
Number of subjects: 162
Study 8399251 — intervention group
Group type: EXPERIMENTAL
Intervention: Number of previous x‐rays and previous broken appointments
Number of subjects: 162
Study 8399251 — intervention group
Group type: EXPERIMENTAL
Intervention: Health Belief Model
Number of subjects: 162
Study 3091801 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefadroxil 30 mg/kg once daily for 10 days
Number of subjects: 196
Study 3091801 — intervention group
Group type: COMPARATOR
Intervention: Penicillin V 250 mg three times daily for 10 days
Number of subjects: 196